Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$35.50

-1.97 (-5.26%)

18:03
11/28/16
11/28
18:03
11/28/16
18:03

Blueprint Medicines 'encouraged' by early Phase 1 BLU-554 trial data

Blueprint Medicines Corporation announced data from its ongoing Phase 1 trial evaluating BLU-554, an investigational medicine for the treatment of advanced hepatocellular carcinoma. Blueprint Medicines is developing BLU-554 as a potent, highly selective inhibitor of fibroblast growth factor receptor 4. The data are being presented on Tuesday, November 29, 2016, at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. "We are very encouraged to see early anti-tumor activity in patients with confirmed FGF19 overexpression and consistent evidence of FGFR4 pathway modulation during the dose escalation part of this first-in-human clinical trial," said Andy Boral, M.D., Chief Medical Officer of Blueprint Medicines. "Now that we have demonstrated proof-of-concept, determined the maximum tolerated dose, and implemented FGF19 biomarker screening globally, we can move rapidly to enroll patients in the expansion part of the study to more fully evaluate the activity of BLU-554 in patients with advanced HCC." BLU-554 was evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with advanced HCC. As of the data cutoff date of November 7, 2016, 25 patients had been treated in the dose escalation portion of the Phase 1 clinical trial at five dose levels, with the majority of patients having previously received sorafenib. The study was designed to retroactively assess patient biopsies for FGFR4 pathway activation after enrollment by evaluating levels of FGF19, the protein that activates FGFR4, using an investigational immunohistochemistry assay. Prospective screening of patients with the investigational IHC assay was implemented during dose escalation, enabling enrollment of enrichment patients with confirmed FGF19 overexpression which resulted in a larger number than anticipated of biomarker positive patients being enrolled. Blueprint Medicines has initiated the expansion portion of the Phase 1 clinical trial, and enrollment is ongoing. Pharmacokinetic data across all dose levels showed rapid oral absorption, a mean half-life of approximately ten hours, and exposure in the expected therapeutic range based on HCC xenograft models. Blueprint Medicines has initiated enrollment of the biomarker-selected expansion cohorts at the maximum tolerated dose of 600 mg QD. In the expansion, patients will be prospectively evaluated for tumor expression of FGF19 using an investigational IHC assay. We plan to enroll approximately 45 patients in three subsets. Two subsets of patients will be selected to have tumors that overexpress FGF19, which indicates autocrine physiology, where FGF19 is produced by the tumor cells in the liver. One of the patient subsets with tumors that overexpress FGF19 will also have FGF19 gene amplification. The third subset of patients will be selected to have tumor FGF19 expression less than 1% by the IHC assay, which indicates normal endocrine physiology, where FGF19 is produced by the intestine.

  • 29

    Nov

  • 01

    Dec

  • 03

    Dec

  • 05

    Dec

BPMC Blueprint Medicines
$35.50

-1.97 (-5.26%)

05/27/16
RAJA
05/27/16
INITIATION
Target $23
RAJA
Outperform
Blueprint Medicines initiated with an Outperform at Raymond James
Raymond James analyst Chris Raymond initiated Blueprint Medicines with an Outperform rating and $23 price target. The analyst thinks Blueprint's unique kinase inhibitor discovery platform is well-positioned to generate novel compounds for years to come. Coupling this with a clinical stage pipeline that remains wholly-owned, key proof-of-concept data for two products,BLU-285 and BLU-554, in three different indications by year end 2015, and a valuation offering favorable risk/reward.
08/05/16
ADAM
08/05/16
INITIATION
Target $26
ADAM
Buy
Blueprint Medicines initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Blueprint Medicines with a Buy and $26 price target.
11/11/16
ADAM
11/11/16
NO CHANGE
Target $35
ADAM
Buy
Blueprint Medicines price target raised to $35 from $26 at Canaccord
Canaccord analyst Arlinda Lee raised her target on Blueprint Medicines to $35 from $26 following company updates on its pipeline of novel, rationally designed, target kinase inhibitors. The analyst increased her probability of success for the company's three programs to 25% from 20% and maintained her Buy rating on Blueprint Medicines shares.

TODAY'S FREE FLY STORIES

BA

Boeing

$176.59

1.2274 (0.70%)

11:05
02/23/17
02/23
11:05
02/23/17
11:05
Hot Stocks
Boeing reports 31 new orders in weekly update »

Boeing, on its website,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

11:05
02/23/17
02/23
11:05
02/23/17
11:05
General news
52-Week Bill Announcement CUSIP Number data reported »

52-Week Bill Announcement…

11:05
02/23/17
02/23
11:05
02/23/17
11:05
General news
52-Week Bill Announcement Offering Amount data reported »

52-Week Bill Announcement…

11:05
02/23/17
02/23
11:05
02/23/17
11:05
General news
6-Month Bill Announcement CUSIP Number data reported »

6-Month Bill Announcement…

11:05
02/23/17
02/23
11:05
02/23/17
11:05
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

FRTA

Forterra

$18.52

-0.14 (-0.75%)

11:04
02/23/17
02/23
11:04
02/23/17
11:04
Conference/Events
Forterra management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 30

    Mar

LMT

Lockheed Martin

$263.90

-2.025 (-0.76%)

11:03
02/23/17
02/23
11:03
02/23/17
11:03
Hot Stocks
Trump says Lockheed Martin cut plane costs by $700M »

President Trump, during a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LHCG

LHC Group

$49.26

0.36 (0.74%)

11:02
02/23/17
02/23
11:02
02/23/17
11:02
Conference/Events
LHC Group management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 09

    Mar

  • 21

    Mar

NTT

Nippon Telegraph

$42.17

0.22 (0.52%)

11:02
02/23/17
02/23
11:02
02/23/17
11:02
Hot Stocks
NTT Communication to acquire 100% ownership of RagingWire Data Centers »

RagingWire Data Centers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLSE

Pulse Biosciences

$14.49

0.66 (4.77%)

11:01
02/23/17
02/23
11:01
02/23/17
11:01
Periodicals
Pulse Biosciences mentioned cautiously by TheStreetSweeper 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:01
02/23/17
02/23
11:01
02/23/17
11:01
General news
Kansas City Fed Manufacturing Index Level data reported »

February Kansas City Fed…

NLSN

Nielsen

$45.10

0.215 (0.48%)

11:01
02/23/17
02/23
11:01
02/23/17
11:01
Hot Stocks
Nielsen says Univision signs multiyear agreement with Nielsen Audio »

Nielsen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

FEYE

FireEye

$11.23

-0.57 (-4.83%)

11:01
02/23/17
02/23
11:01
02/23/17
11:01
Options
Call buyers jump as FireEye shares catch fire »

Call buyers jump as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

11:00
02/23/17
02/23
11:00
02/23/17
11:00
General news
EIA crude inventories for week of February 17 »

Crude oil inventories…

11:00
02/23/17
02/23
11:00
02/23/17
11:00
General news
Treasury 7-year auction outlook: »

Treasury 7-year auction…

10:55
02/23/17
02/23
10:55
02/23/17
10:55
General news
U.S. tax refunds »

U.S. tax refunds are…

ORCL

Oracle

$42.84

0.33 (0.78%)

10:51
02/23/17
02/23
10:51
02/23/17
10:51
Options
Large option block opened in Oracle as shares reach 52-week highs »

Large option block opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:50
02/23/17
02/23
10:50
02/23/17
10:50
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

NVDA

NVIDIA

$110.76

-0.31 (-0.28%)

, INTC

Intel

$36.07

-0.45 (-1.23%)

10:50
02/23/17
02/23
10:50
02/23/17
10:50
Hot Stocks
Analysts say sell NVIDIA amid competitive changes, gaming slowdown »

Shares of NVIDIA (NVDA)…

NVDA

NVIDIA

$110.76

-0.31 (-0.28%)

INTC

Intel

$36.07

-0.45 (-1.23%)

AMD

AMD

$14.28

0.28 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 19

    Mar

  • 04

    Apr

  • 05

    Apr

AMCX

AMC Networks

$57.50

-0.19 (-0.33%)

10:46
02/23/17
02/23
10:46
02/23/17
10:46
Hot Stocks
AMC Networks sees Q1 as most challenging time for AOI comps »

On the call, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FCX

Freeport McMoRan

$13.77

0.0354 (0.26%)

10:46
02/23/17
02/23
10:46
02/23/17
10:46
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

HD

Home Depot

$145.90

0.65 (0.45%)

, LOW

Lowe's

$76.75

-0.055 (-0.07%)

10:45
02/23/17
02/23
10:45
02/23/17
10:45
Hot Stocks
Analyst says buy Home Depot as market underestimates housing recovery »

Morgan Stanley upgraded…

HD

Home Depot

$145.90

0.65 (0.45%)

LOW

Lowe's

$76.75

-0.055 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 05

    Mar

  • 15

    Mar

  • 19

    Mar

10:44
02/23/17
02/23
10:44
02/23/17
10:44
Hot Stocks
Breaking Hot Stocks news story  »

Reading International…

AMCX

AMC Networks

$57.50

-0.19 (-0.33%)

10:42
02/23/17
02/23
10:42
02/23/17
10:42
Hot Stocks
AMC Networks sees continued growth in international cable networks »

The company noted that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

ARNC

Arconic

$30.50

-0.05 (-0.16%)

10:42
02/23/17
02/23
10:42
02/23/17
10:42
Hot Stocks
Elliott reiterates recommendation Arconic board consider Lawson as next CEO »

Elliott Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.